Back to News
Market Impact: 0.15
PureTech Founded Entity Seaport Therapeutics Presents Additional Pharmacokinetic Data from Phase 1 Clinical Trial of GlyphAgo™ at the 39th European College of Neuropsychopharmacology (ECNP) Congress
Source: Business Wire
Healthcare & Biotech
Seaport Therapeutics, a PureTech-founded entity, presented data from a Phase 1 trial of GlyphAgo at the European College of Neuropsychopharmacology Congress. The headline provides no trial results, numerical outcomes, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
PRTC0.10
SPTX0.60
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down
- Baird upgrades Humana stock rating on margin recovery outlook
- HIMS jumps 7% on peptide tailwind — but Citi sees 17% downside from here